APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1-2 μg/ml |
2 μg/ml |
10-40 μg/ml |
Not tested in other applications.
Calculated MW
Product Note
The biological activity is measured by its ability to neutralize recombinant human IGFBP-1 in the presence of recombinant human IGF-I.
PROPERTIES
Form
Liquid
Buffer
PBS
Preservative
No preservative
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
purified recombinant human insulin-like growth factor binding protein 1, expressed in E. coli.
Purification
Purified immunoglobulin
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
insulin like growth factor binding protein 1 , AFBP , IBP1 , IGF-BP25 , PP12 , hIGFBP-1
Cellular Localization
Secreted
Background
Insulin like growth factor binding protein 1 (IGFBP1) is a member of the superfamily of insulin like growth factor (IGF) binding proteins which include six high affinity IGF binding proteins (IGFBP) and at least four low affinity binding proteins referred to as IGFBP related proteins (IGFBPrP). The IGFBP members are cysteine rich proteins with conserved cysteine residues clustered in the amino-terminal and the carboxy terminal regions of the molecule. Contained within IGFBP1 and 2 is an integrin receptor recognition sequence (RGD) that is responsible for promoting cell migration by an IGF independent action. IGFBPs hold a central position in IGF ligand receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment. IGFBPs will either inhibit or enhance the biological activities of IGF or act in an IGF independent manner. Post-translational modification of IGFBPs, including phosphorylation and proteolysis, will modify the affinities of the binding proteins for IGF and may indirectly regulate IGF actions. IGFBP1 is expressed in liver, decidua, and kidneys and is the major IGF binding protein in human amnionic fluid. In hepatocytes, IGFBP1 production is regulated at the transcriptional level due to the effects of insulin and corticosteriods. IGFBP1 is the major determinant of the level of free IGF in serum. The expression of IGFBP1 is inhibited by insulin, IGFI, and IGFII and is stimulated by glucocorticoids, thyroid hormone, and epidermal growth factor (EGF), indicating an endocrine function. IGFBP1 shows inhibitory actions on cell proliferation and differentiation, presumably by interfering with the interactions between IGF and the IGF receptor (IGFR).
Database
Research Area
REFERENCE
There are currently no references for IGFBP1 antibody [33627.11] (GTX10732). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for IGFBP1 antibody [33627.11] (GTX10732). Be the first to share your experience with this product.